You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 289 No. 3, January 15, 2003 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (7)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA

Lung Cancer Screening at Any Price?

Victor R. Grann, MD, MPH; Alfred I. Neugut, MD, PhD

JAMA. 2003;289:357-358.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Most biomedical research focuses on the quest to discover new methods for reducing morbidity and mortality from serious illnesses. Once these interventions are created and developed, the next steps in science are directed toward confirmation of the efficacy and effectiveness of these interventions and then estimating their potential impact. On some level, for most investigators, this represents the be-all and end-all of research.

The last decade of medical practice and the changes that have occurred have led to a dramatic alteration in how clinicians perceive the utility of these interventions. No longer is it sufficient that a medication or procedure prolong life or even cure the patient. Today, medical costs also play a role in assessments and judgments of what interventions to use and under what circumstances to use them. In an era of limited resources, these judgments enable physicians . . . [Full Text of this Article]

Author Affiliations: Department of Medicine and Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons; Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY.


RELATED ARTICLE

Lung Cancer Screening With Helical Computed Tomography in Older Adult Smokers: A Decision and Cost-effectiveness Analysis
Parthiv J. Mahadevia, Lee A. Fleisher, Kevin D. Frick, John Eng, Steven N. Goodman, and Neil R. Powe
JAMA. 2003;289(3):313-322.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Three-year findings of an early lung cancer detection feasibility study with low-dose spiral computed tomography in heavy smokers
Novello et al.
Ann Oncol 2005;16:1662-1666.
ABSTRACT | FULL TEXT  

Como International Conference Position Statement: Lung Cancer Screening for Early Diagnosis 5 Years After The 1998 Varese Conference
Strauss et al.
Chest 2005;127:1146-1151.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2003 American Medical Association. All Rights Reserved.